Related Experiment Video
Updated: Aug 14, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Cyclosporine and gingival overgrowth
1Department of Pathology, University of Adelaide, South Australia.
Journal of Oral Pathology
|October 1, 1987
Summary
Cyclosporine medication can cause gingival overgrowth, particularly in renal transplant patients. This condition involves inflamed gums exacerbated by plaque and calculus, indicating local factors interacting with the drug.
Area of Science:
- Oral Medicine
- Pharmacology
- Transplantation Medicine
Background:
- Cyclosporine is an immunosuppressant commonly used after organ transplantation.
- Gingival overgrowth is a known side effect of certain medications, including cyclosporine.
- Understanding the pathogenesis of drug-induced gingival overgrowth is crucial for patient management.
Observation:
- A case study presented a renal transplant patient experiencing cyclosporine-induced gingival overgrowth.
- The overgrown gingival tissues were inflamed and associated with significant plaque and calculus deposits.
- Histological analysis revealed fibro-epithelial changes and inflammatory cell infiltration in the affected gums.
Findings:
- In vitro studies showed fibroblasts from overgrown gingival tissue had slower proliferation rates and reduced protein production compared to normal fibroblasts.
- These findings suggest a site-specific alteration in fibroblast behavior.
- The gingival overgrowth appears to be a result of local factors, such as plaque and calculus, being exacerbated by cyclosporine therapy.
Implications:
- This case highlights the importance of meticulous oral hygiene in patients taking cyclosporine.
- Further research into fibroblast behavior in drug-induced gingival overgrowth is warranted.
- Management strategies may need to address both the medication and local oral factors.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:27The Oral Microbiota
The oral microbiome includes a complex ecosystem comprising over 700 microbial species, identified through genomic sequencing and culture-based analyses to date. This community includes a core microbiome, found universally among individuals, and a variable component influenced by environmental factors such as diet, lifestyle, and host genetics. Site-specific conditions, including oxygen gradients, pH levels, and nutrient availability, determine the spatial distribution of these microorganisms...